Few molecular-guided therapeutics have proven efficacy for sarcomas; these are limited to imatinib and others for KIT- or PDGFRA-mutated GIST and COL1A1(A3)-PDGFA(D) fusion-driven dermatofibrosarcoma protuberans (DFSP), and multi-tyrosine kinase inhibitors for ALK and NTRK fusion-driven inflammatory myofibroblastic tumors (IMT) and sarcoma NOS11–14. Here, PDGFRA is linked to inflammatory myofibroblastic tumor.